Pathophysiologic Effects of Uremic Retention Solutes (1999)

The uremic syndrome can be defined as a deterioration of biochemical and physiologic functions, in parallel with the progression of renal failure, resulting in complex and variable symptomatology (1,2,3). The compounds that accumulate in the uremic blood and tissues during the development of end-stage renal disease (ESRD), directly or indirectly due to a deficient renal clearance, are called uremic retention solutes. These retention solutes may modify biochemical or physiologic functions; if they do so, they contribute to the uremic syndrome. Only a few solutes have an established role as uremic toxins. According to Bergoström, apart from inorganic compounds, urea, oxalic acid, parathyroid hormone (PTH), and β2-microglobulin conform to the most strict definition of uremic toxins (4). However, this does not preclude a potential toxic role for various other retention solutes (5). The following factors, which are not always considered, might affect uremic solute concentration and their impact on biologic functions. (1) In addition to classical sources of uremic solutes such as dietary protein breakdown, alternative sources such as environment, herbal medicines, or psychedelic drugs may play a role in uremic toxicity. (2) Many solutes with toxic capacity enter the body through the intestine. Changes in the composition of intestinal flora, or changes in intestinal production and absorption, might alter their serum concentration. (3) Some uremic solutes interfere with functions that directly affect the biochemical action of other solutes: the expression of PTH receptors, the response to 1,25(OH)2 vitamin D3, as well as the protein binding and breakdown of several other solutes. (4) Most uremic patients are prescribed a host of drugs. Interference of drugs with protein binding and/or tubular secretion of uremic solutes will influence their biologic effect. (5) Lipophilic compounds may be responsible at least in part for functional alterations in uremia. (6) The impact of residual renal function on uremic solute retention should not be neglected. (7) The main strategy that has been used up to now to decrease uremic solute concentration is dialysis, but dialysis is nonspecific and removes essential compounds as well. (8) Uremic solutes accumulate not only in the plasma but also in the cells, where most of the biologic activity is exerted. Removal of intracellular compounds during dialysis through the cell membrane may be hampered, resulting in multicompartmental kinetics and inadequate detoxification. It is of note that lower morbidity and mortality are observed in patients submitted to long dialysis sessions (6,7). Compounds may be cleared more efficiently with continuous or long-lasting low efficiency strategies, because removal is more gradual. Our views on the uremic syndrome and several uremic solutes have changed substantially during the last decade. Therefore, it was thought timely to summarize the present state of knowledge about the biochemical, physiologic, and/or clinical impact of those compounds that have been subjected to relatively thorough evaluation during these last 10 years. Specific attention was also paid to generation and removal patterns. Urea In spite of the extensive number of studies to which urea has been submitted relative to its toxicity, the number of reports in which a well-defined adverse biochemical or physiologic impact has been reported is relatively low. However, in a classical study by Johnson et al., it was demonstrated that dialysis against dialysate containing high urea concentrations worsens clinical symptoms (8). Several recent studies point to an important pathophysiologic impact of urea. Lim et al. have shown that urea inhibits NaK2Cl cotransport in human erythrocytes (9), as well as a number of cell volume-sensitive transport pathways. The NaK2Cl cotransport is a ubiquitous process that serves numerous vital functions, among which cell volume and extrarenal potassium regulation are the most important. Extracellular urea also decreases cAMP production, albeit at concentrations exceeding those observed in clinical uremia (10). The presence of urea in blood has been held responsible for a decreased affinity of oxygen for hemoglobin because of 2,3-diphosphoglycerate binding (11). Urea inhibits macrophage inducible nitric oxide synthesis at the posttranscriptional level (12). Apart from its direct toxicity, urea is a precursor of some of the guanidines, especially guanidinosuccinic acid (see below), which by itself induces direct biochemical alterations. As the most important osmotically active solute, urea may also provoke dialysis dysequilibrium, if the decrease in plasma concentration during dialysis occurs too rapidly. Urea is unequivocally recognized as a marker of solute retention and removal in dialyzed patients. It is one of the few solutes that have been correlated convincingly with clinical outcome of hemodialysis (13). However, it is not the peak concentration per se, but the low reduction ratios during dialysis and more likely the high ambient level (time average) that are related to increased mortality (14). Hence, high blood concentrations of urea do not necessarily relate to a poor outcome if removal is sufficient (e.g., in continuous ambulatory peritoneal dialysis [CAPD] patients and/or in patients receiving a high protein diet) (15). Middle Molecules/Peptides More than a decade ago, middle molecules (molecular weight [MW] range, 300 to 12,000 D) were held responsible for the uremic syndrome, but it was difficult to identify the exact structure of the responsible molecules (1). Nevertheless, several clinical, metabolic, and/or biochemical disturbances are caused by uremic compounds that conform with the middle MW range. Chromatographic fractions with a MW between 1 and 5 kD extracted from uremic human ultrafiltrate inhibit appetite and suppress food intake in animals (16). A 500- to 2000-D subfraction of uremic serum inhibits apolipoprotein (apo) A-I secretion in a human hepatoma cell line (17), which may be related to atherogenicity. Andress et al. described an inhibitor of osteoblast mitogenesis originating from uremic plasma with a MW between 750 and 900 D (18). Dialysis membranes with a capacity to remove middle molecules (high flux membranes) have been related to lower morbidity and mortality (19,20,21,22); however, at the same time these highly efficient membranes are often less complement-activating than their counterpart unmodified cellulose in many studies. Hence, the relative importance of the levels of middle molecules versus biocompatibility-related events is not always clear. Some of the recently defined uremic compounds, e.g., β2-microglobulin (β2M) and advanced glycosylation end products (AGE), as well as PTH, conform to the structural definition of middle molecules. Because of the large amount of information on the biochemical impact of these three compounds, they will be discussed separately in the following subsections. β2-Microglobulin β2M (MW approximately 12,000 D) is a component of the major histocompatibility antigen. Dialysis-related amyloid, as found in amyloid bone disease and carpal tunnel syndrome after long-term dialysis, is to a large extent composed of β2M. Recent data demonstrate that this amyloidosis develops earlier than previously suspected. In some patients it is observed after 1 to 2 yr of dialysis, in the setting of both hemodialysis and peritoneal dialysis (23,24). Advanced glycosylation end products (see section below) and β2M are closely related. AGE-modified β2M has been identified in the amyloid of hemodialyzed patients (25). At least three major AGE modifications of β2M may play a role: pentosidine-β2M (26), carboxymethyllysine-β2M (25,27), and imidazolone-β2M (28). AGE-modified β2M enhances monocytic migration and cytokine secretion (29), suggesting that foci containing AGE-β2M may initiate an inflammatory response leading to bone and joint destruction. On the other hand, AGE modification is not essential for β2M-related tissue destruction (30). β2M-related compounds might also be involved in other aspects of the uremic syndrome. One of the peptides with a granulocyte inhibitory effect described by Haag-Weber et al. had partial homology with β2M (31). Commercially available assays for concentration measurements of intact β2M cross-react with this peptide, resulting in an overestimation of true β2M concentration in uremic plasma samples. Serum β2M levels are generally lower in CAPD patients when compared with hemodialysis patients (32), but this might be attributable at least in part to better conservation of endogenous residual renal function. Although the clinical expression of dialysis-related amyloidosis disappears after kidney transplantation, the underlying pathologic processes such as bone cysts and tissular β2M deposits remain present (33). Because β2M is only removed by dialyzers with a large pore size, it may be representive in its kinetic behavior of other large molecules. Apart from its role in amyloidosis, the biologic impact of β2M seems to be minor. Parathyroid Hormone PTH, a middle molecule with a MW of ±9000 D, is generally recognized as a major uremic toxin, although its increase in concentration during ESRD is merely attributable to enhanced glandular secretion, rather than to decreased removal by the kidneys. Excess PTH gives rise to an increase in intracellular calcium, resulting in disturbances in the function of virtually every organ system, including bone mineralization, pancreatic response, erythropoiesis, and immune, cardiac, and liver function (34,35,36,37,38). PTH is one of the few substances that has been causally linked to uremic neuropathy, and it plays a role in fibroblast activation. PTH is also related to a number of uremic symptoms, e.g., pruritus. Downregulation of PTH-PTHrP receptor mRNA expression is observed in liver, kidney, and heart of rats with advanced chronic renal failure (39,40). Parathyroidectomy does not entirely prevent PTH/PTHrP receptor downregulation (41), suggesting that this alteration depends on more than elevated PTH alone. The increased PTH concentration in uremia is the result of a number of compensatory homeostatic mechanisms. Hyperparathyroidism results at least in part from phosphate retention, decreased production of calcitriol (1,25(OH)2 vitamin D3), and/or hypocalcemia. Therapy with calcitriol or one of its analogues lowers serum PTH levels (42). It not only suppresses PTH release, but may also restore the secretory reserve of the parathyroid gland during hypocalcemia (42). Advanced Glycosylation End Products Glucose and other reducing sugars react nonenzymatically with free amino groups to form reversible Schiff base adducts (in days) and stable Amadori products (in weeks), which are then converted into AGE through chemical rearrangements and dehydration reactions (43), as first described by Maillard. Several AGE compounds are peptide-linked degradation products (MW 2000 to 6000 D) (44). Among the postulated structures for AGE are imidazolone, pyrrole aldehyde, pentosidine, and Nε-(carboxymethyl)lysine. Schiff base formation affects the interaction of the vitamin D receptor with responsive DNA elements, such as osteocalcin, vitamin D-responsive elements (VDRE), or constructed VDRE attached to a cat reported gene in transfected cells (45). AGE cause an inflammatory reaction in monocytes by the induction of interleukin-6, tumor necrosis factor-α, and interferon-γ (46). AGE-modified β2M may play an important role in the formation of dialysis-associated amyloidosis (29) (see earlier section). AGE can react with and chemically inactivate nitric oxide (NO) (47), a potent endothelium-derived vasodilator, anti-aggregant, and antiproliferative factor. AGE also induce oxidative protein modification (48). Transferrin and lysozyme, after contact with AGE-modified albumin, lose their immune-enhancing properties (49). It is of note that food contains AGE and that AGE are absorbed intestinally (26). AGE are retained not only in renal failure but also in diabetes mellitus and aging, where they are held responsible for tissue damage and functional disturbances. Specific receptors for AGE have been identified (RAGE), and their expression is already enhanced during moderate uremia (50). Serum concentrations of AGE are higher in dialyzed ESRD patients without diabetes mellitus than in nonuremic diabetic patients; in the uremic population, they do not depend on the glycemic status (26,51). Diabetic patients with ESRD have the highest AGE levels. Increased serum concentrations in ESRD patients might be attributed to increased intake, production, and/or retention. In spite of continuous contact with glucose, CAPD patients do not have higher serum AGE levels when compared with hemodialysis patients (44). Nevertheless, protein glycation has been demonstrated in the peritoneal membrane (52). This group of molecules highlights the growing interest of attempting to remove more of the larger molecules with dialysis that are retained in uremia, and perhaps to initiate more specific removal via adsorption columns. Other Middle Molecules Granulocyte inhibiting protein I (GIP I), recovered from uremic sera or ultrafiltrate, affects various functions of the polymorphonuclear cells involved in the killing of invading bacteria (53). The compound has structural analogy with the variable part of kappa light chains. Another peptide with granulocyte inhibitory effect (GIP II) has partial homology with β2M, and inhibits granulocyte glucose uptake and respiratory burst activity (31). It was extracted from uremic ultrafiltrate (31) and CAPD dwell fluid (54). A degranulation inhibiting protein (DIP), identical to angiogenin, was isolated from a plasma ultrafiltrate obtained from high flux membranes and from peritoneal effluent of uremic patients (55). The structure responsible for the inhibition of degranulation is different from the sites responsible for the angiogenic or ribonucleolytic activity of angiogenin. A modified variant of ubiquitin inhibits polymorphonuclear chemotaxis (56). In none of these studies are the exact concentrations in uremic sera or biologic fluids reported. Molecules with a Molecular Weight in Excess of 12 kD The kinetic behavior in dialysis of molecules with a molecular weight above 12 kD should be comparable to that of the somewhat smaller true middle molecules. Serum concentrations of cystatin C (13.3 kD), Clara cell protein (CC16) (15.8 kD), and retinol binding protein (RBP) (21.2 kD) are elevated in renal failure (57). Cystatin C is a cystein-proteinase inhibitor. CC16 is an α-microprotein, playing an immunosuppressive role in the respiratory airways (58). Leptin, a 16-kD plasma protein suppressing appetite (59) and inducing weight reduction in mice (60), is retained in renal failure (61). The increase in serum leptin is almost entirely due to a rise in the free (non-protein-bound) concentration (61), and has been suggested to play a role in the decreased appetite of uremic patients. Increased leptin is associated with low protein intake and loss of lean tissue (62). Recent data suggest an inverse correlation in uremia between leptin and indices of nutritional status such as serum albumin or lean body mass (63), and a direct correlation with C-reactive protein (64). However, leptin levels are also elevated in obese people and hence are not necessarily related to reduced appetite. Body fat and serum leptin correlate positively in uremia (64). Therefore, the biochemical role of leptin in renal failure remains inadequately defined. Guanidines The guanidines are a large group of structural metabolites of arginine. Among them are uremic retention such as and Several of the compounds modify biologic functions. has been held responsible for the of cells although only at concentrations exceeding 5 those in and is a precursor of acid and acid inhibit production acid, acid, and induce after and/or in animals A of compounds suppresses the cell response to which is also a enhances the production of Some of the other guanidines as are of nitric oxide The inhibition of synthesis results in and and changes is the most specific endogenous compound with inhibitory on In the and inhibition of These might be of in of the relatively high concentrations of the in the The concentration of is increased in ESRD and has been in the development of The increase in is more but this compound is less endogenous only a to inhibitory activity on and compared to compounds such as In to the of inhibition of synthesis in uremia, et al. to an enhanced production in at least some uremic which was related to uremic The generation of the guanidines from in the such as acid and is in ESRD On the other hand, the synthesis of guanidinosuccinic acid, and is which can be attributable to urea retention is not in dialyzed in where production is increased due to a alteration of In ESRD patients without plasma levels are increased approximately compared with in ESRD patients without is by of in the and blood although the is rather These events were reported with dialysis in the of renal but are now less in the presence of intake of e.g., acid, or or in the presence of inflammatory disease The role of in in uremia remains a of In rats with chronic renal failure, results in increased and renal function However, up to 300 for 1 not plasma levels or affect generation of in CAPD patients at on the other caused a decrease in concentration in hemodialysis patients of however, induce levels of are related to and phosphate PTH levels a of of plasma calcitriol inhibits and hence the production of the active vitamin D retention is also involved in changes of by a decrease in the activity of the responsible for their degradation these events result in intestinal and the development of a state of the intestinal At least in phosphate has an effect on the progression of renal The results are less in The blood concentration is the result of protein and protein intake as well as the of other dietary sources (e.g., of protein intake the of which can be by the of phosphate The effect of the however, is often especially in with a high is a and compound with a MW of only serum concentration is elevated in renal failure It is toxic for inducing from liver and the which plays a role in the of to Several other functions, such as oxygen uptake protein binding and the of the cell membrane are as well. inhibits various processes related to the production of free which are involved in the destruction of bacteria by uptake and the toxic effect of on the are increased in the presence of is an end of protein by the intestinal as a result of the of and sources and Specific is which is present in several used herbal medicines, and psychedelic drugs of the intestinal of by of decreases the serum concentration in rats is a amino acid that is by the of retention results in the of an toxic compound that with and inhibits which may be caused by a in breakdown or by vitamin or is an for disease in the The is as as for with chronic renal failure have serum levels to above is the most in ESRD and is present at increased concentrations in kidney with disease serum concentration however, not only on the of kidney failure, but also on nutritional intake (e.g., of vitamin status (e.g., of and renal the of cells, one of the most of The of of the precursor to rats induces alterations in the also several functions, resulting in enhanced levels can be reduced by acid, vitamin and/or vitamin the with ESRD might higher of than the nonuremic clinical of the of concentration in uremia to not is by the liver from which is by the intestinal as a of It enhances by with drugs at the protein binding sites inhibits the active tubular secretion of these compounds and inhibits of by It is that uremic retention solutes induce their removal by peritoneal dialysis or by the progression of intact might be one of the for the of The of or of to uremic rats the of progression of and of renal failure are found in various and and some of them are also by the intestinal Several metabolites of are retained in uremia. the same kinetic Some do not conform with the definition of uremic retention solutes because their concentration is rather low in ESRD (e.g., acid is one of the a uremic solute, and one of the major of protein binding It inhibits the renal uptake of acid in kidney and a decrease in renal of various of their and of which are removed via the In in the is by and the at a at least than that of inhibits of by and of in isolated et al. demonstrated a correlation between and plasma concentrations of The uremic syndrome is a complex of clinical on functional changes that may be attributable to one or more different solutes. about the and the kinetic behavior of the responsible compounds might be of when are in the alterations are by a of Some compounds are and (e.g., urea, the guanidines, some are (e.g., and/or protein (e.g., are larger and in the middle molecular (e.g., β2M, PTH, removal of of molecule might be with a different of e.g., by large pore membranes and/or dialyzers or with a high capacity for some or several of the uremic toxins. uptake can be reduced by dietary or by of of residual renal function might be an important to removal of retention solutes. the of marker molecules for uremic retention and removal should be It to be the which are compounds are in their kinetic behavior for middle and for the are to for this